Quanterix (NASDAQ:QTRX – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04), FiscalAI reports. The firm had revenue of $34.97 million for the quarter, compared to analysts’ expectations of $33.85 million. Quanterix had a negative return on equity of 26.09% and a negative net margin of 80.25%.
Quanterix Trading Down 0.3%
Shares of NASDAQ:QTRX opened at $2.89 on Monday. Quanterix has a 12-month low of $2.15 and a 12-month high of $8.77. The business has a 50 day moving average of $3.00 and a two-hundred day moving average of $3.80. The company has a market capitalization of $136.67 million, a PE ratio of -1.10 and a beta of 1.06.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on QTRX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Quanterix in a report on Wednesday. TD Cowen increased their price objective on shares of Quanterix from $3.00 to $3.50 and gave the company a “hold” rating in a research report on Tuesday, October 13th. Wall Street Zen cut shares of Quanterix from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Canaccord Genuity Group lowered their target price on shares of Quanterix from $4.00 to $3.00 and set a “hold” rating for the company in a research note on Monday, August 17th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $3.25.
View Our Latest Research Report on Quanterix
About Quanterix
Quanterix Corporation (NASDAQ:QTRX) is a life sciences company that develops ultra-sensitive digital immunoassay technologies for detecting and measuring biomarkers in blood and other biological samples. Its platform is designed to identify proteins and other molecules at very low concentrations, supporting research into disease biology, diagnosis, treatment response and drug development.
The company’s principal technology, Simoa, uses digital detection methods to improve the sensitivity of immunoassays.
Read More
- Five stocks we like better than Quanterix
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.
